Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Steve Fancy who wrote (5248)	9/2/1998 12:52:00 PM
From: Izzy	Read Replies (2) \| Respond to of 6136

Fascinating info. Steve, thanks. Haven't received investor's package yet, so it's difficult, at this time, for me to quickly analyze the info. As I understand it, since AGPH is profitable, AGPH is actually considered to be a pharmaceutical company and not a biotech company. The new Agouron Oncology Division, nonprofitable, would be a biotech. Since it appears that there will be a significant increase in the number of AGPH shares, the future P/Es would significantly decrease (hopefully not the stock price). The report doesn't state just how many shares of the new Oncology Division Common Stock will be given to present AGPH stockholders.